Demo Data from EDBT 2026 / reviewers in the wild / expert
Miguel Castresana Aguirre
dblp:332/2518
· DBLP profile ↗
2ranked-venue papers
0as first author
2since 2021 · last 2024
0000-0002-4665-6537ORCID · reported
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 2 · 2 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 2 heaviest of 3, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › systems bioinformatics › pathway analysis
network-based pathway analysis |
0.6 | 1 | 2022 | PathwAX II: network-based pathway analysis with interactive visualization of network crosstalk · Bioinform. 2022 |
Bioinformatics and computational biology › systems bioinformatics
pathway analysis |
0.6 | 1 | 2022 | PathwAX II: network-based pathway analysis with interactive visualization of network crosstalk · Bioinform. 2022 |
Methods — techniques the papers use, named apart from their topics
binox algorithm · 0.6
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2024 | Benchmarking enrichment analysis methods with the disease pathway networkabstractEnrichment analysis (EA) is a common approach to gain functional insights from genome-scale experiments. As a consequence, a large number of EA methods have been developed, yet it is unclear from previous studies which method is the best for a given dataset. The main issues with previous benchmarks include the complexity of correctly assigning true pathways to a test dataset, and lack of generality of the evaluation metrics, for which the rank of a single target pathway is commonly used. We here provide a generalized EA benchmark and apply it to the most widely used EA methods, representing all four categories of current approaches. The benchmark employs a new set of 82 curated gene expression datasets from DNA microarray and RNA-Seq experiments for 26 diseases, of which only 13 are cancers. In order to address the shortcomings of the single target pathway approach and to enhance the sensitivity evaluation, we present the Disease Pathway Network, in which related Kyoto Encyclopedia of Genes and Genomes pathways are linked. We introduce a novel approach to evaluate pathway EA by combining sensitivity and specificity to provide a balanced evaluation of EA methods. This approach identifies Network Enrichment Analysis methods as the overall top performers compared with overlap-based methods. By using randomized gene expression datasets, we explore the null hypothesis bias of each method, revealing that most of them produce skewed P-values. Davide Buzzao, Miguel Castresana Aguirre, Dimitri Guala, Erik L. L. Sonnhammer |
Briefings Bioinform. | 2 |
| 2022 | PathwAX II: network-based pathway analysis with interactive visualization of network crosstalkabstractMOTIVATION: Pathway annotation tools are indispensable for the interpretation of a wide range of experiments in life sciences. Network-based algorithms have recently been developed which are more sensitive than traditional overlap-based algorithms, but there is still a lack of good online tools for network-based pathway analysis. RESULTS: We present PathwAX II-a pathway analysis web tool based on network crosstalk analysis using the BinoX algorithm. It offers several new features compared with the first version, including interactive graphical network visualization of the crosstalk between a query gene set and an enriched pathway, and the addition of Reactome pathways. AVAILABILITY AND IMPLEMENTATION: PathwAX II is available at http://pathwax.sbc.su.se. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Christoph Ogris, Miguel Castresana Aguirre, Erik L. L. Sonnhammer |
Bioinform. | 2 |